Currents in Pharmacy Teaching and Learning
Volume 2, Issue 1 , Pages 52-66 , January 2010

Drug structure and treatment algorithms: treatment of hypertension

  • Naser Z. Alsharif, PharmD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author: Naser Z. Alsharif, PharmD, PhD, School of Pharmacy and Health Professions, Creighton University Medical Center, 2500 California Plaza, Omaha, NE 68178

References 

  1. Accreditation Council on Pharmaceutical Education. Accreditation Standards and Guidelines for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. http://www.acpe-accredit.org/standards/default.aspAccessed February 4, 2010
  2. Alsharif NZ, Theesen KA, Roche VF. Structurally-based therapeutic evaluation (SBTE): a therapeutic and practical approach to teaching medicinal chemistry. Am J Pharm Educ. 1997;61:55–60
  3. Alsharif NZ, Roche VF, Destache C. Teaching medicinal chemistry to meet outcome objectives for pharmacy graduates. Am J Pharm Educ. 1999;63:34–40
  4. Alsharif NZ, Shara M, Roche VF. Structurally-based therapeutic evaluation (SBTE): an opportunity for curriculum integration and interdisciplinary teaching. Am J Pharm Educ. 2001;65:314–323
  5. Roche VF, Alsharif NA, Ogunbadeniyi AM. Reinforcing the relevance of medicinal chemistry to the practice of pharmacy through the Who Wants to Be a Med. Chem. Millionaire learning game. Am J Pharm Educ. 2004;68:Article 112
  6. Alsharif NZ, Galt GA, Mehanna A, Chapman R, Ogunbadeniyi AM. Instructional model to teach clinically relevant medicinal chemistry. Am J Pharm Educ. 2006;70:Article 91
  7. Malone PM, Glynn GF, Stohs SJ. The development and structure of a web-based entry level doctor of pharmacy pathway at Creighton University Medical Center. Am J Pharm Educ. 2004;68:Article 46
  8. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML. Pharmacotherapy: A Pathophysiologic Approach. 7th ed.. New York: McGraw-Hill Companies, Inc; 2009;
  9. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL. Applied Therapeutics: The Clinical Use of Drugs. 9th ed.. Baltimore, MD: Lippincott Williams & Wilkins; 2009;
  10. Roche VF. Utilizing chemical knowledge in rational therapeutic decision-making. Am J Pharm Educ. 1985;49:154–157
  11. Currie BL, Chapman RL, Christoff JJ, Sikorski L. Patient related case studies in medicinal chemistry. Am J Pharm Educ. 1994;58:446–450
  12. Harrold MW. Importance of functional group chemistry in the drug selection process: case study. Am J Pharm Educ. 1998;62:24–30
  13. Dimmock JR. Problem solving learning: applications in medicinal chemistry. Am J Pharm Educ. 2000;64:44–49
  14. Segarra-Newnham M. Development of a treatment algorithm for Staphylococcal pyoderma in the emergency department. Hosp Pharm. 2007;42;:226–229
  15. Nassef M, Shapiro G, Casale TB. Identifying and managing rhinitis and its subtypes: allergic and nonallergic components—a consensus report and materials from the Respiratory & Allergic Disease Foundation. Curr Med Res Opin. 2006;22;:2541–2548
  16. Dunn JD, Tierney JG. Step therapy algorithm for the treatment and management of chronic depression. Am J Manag Care. 2006;12;:S335–S343
  17. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens. 2006;20;:255–262
  18. McKenney JM, Davidson MH, Saponaro J, Thompson PD. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005;46;:594–599
  19. Saseen JJ, McLaughlin EJ. Hypertension. In:  Dipiro JT,  Talbert RL,  Yee GC, et al. editor. Pharmacotherapy: A Pathophysiologic Approach. 7th ed.. New York: McGraw-Hill Companies, Inc; 2009;p. 139–171
  20. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  21. McCormick J, Rangno R, Wright JM. Thiazides first-line for hypertension. Can Fam Physician. 2003;49:879
  22. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African-Americans: Consensus statement of the Hypertension in African-American Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541
  23. Gringauz A. Drugs and the cardiovascular diseases. In:  Gringauz A editors. Introduction to Medicinal Chemistry: How Drugs Act and Why?. New York: Wiley-VCH, Inc; 1997;p. 468
  24. Rankin GO. Diuretics. In:  Williams DA,  Lemke TL editor. Foye's Principles of Medicinal Chemistry. 6th ed.. Baltimore, MD: Lippincott Williams & Wilkins; 2008;p. 722–736
  25. Harrold M. Angiotensin converting enzyme inhibitors, antagonists and calcium channel blockers. In:  Williams DA,  Lemke TL editor. Foye's Principles of Medicinal Chemistry. 6th ed.. Lippincott Williams & Wilkins; 2008;p. 738–768
  26. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA guidelines for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e114–e235
  27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretics (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). JAMA. 2002;288:2981–2997
  28. Rybak LP. Pathophysiology of furosemide ototoxicity. J Otolaryngol. 1982;2:27–133
  29. Rybak LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993;5:829–844
  30. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? (Revisiting the meaning of “sulfa allergy”?). Drug Safety. 2001;24:239–247
  31. Alsharif NZ, Galt KA. Effectiveness of an instructional model to teach clinically relevant medicinal chemistry. Am J Pharm Educ. 2006;70:Article 65
  32. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  33. Notghi A, Riemersma RA, Anderton JL, Oliver MF. Effect of pindolol versus atenolol on lipid profile in hypertensive patients. Atherosclerosis. 1989;77:215–220
  34. Fankhauser MP, Freeman MP. Bipolar disorder. In:  Dipiro JT,  Talbert RL,  Yee GC, et al. editor. Pharmacotherapy: A Pathophysiologic Approach. 6th ed.. New York: McGraw-Hill Companies, Inc; 2005;p. 1257–1284
  35. Alsharif NZ, Roche VF, Ogunbadeniyi AM, Chapman R, Bramble JD. Evaluation of performance and learning parity between campus-based and distance-based medicinal chemistry courses. Am J Pharm Educ. 2005;69:Article 33

PII: S1877-1297(10)00005-5

doi: 10.1016/j.cptl.2009.12.006

Currents in Pharmacy Teaching and Learning
Volume 2, Issue 1 , Pages 52-66 , January 2010

Article Tools

* Image Usage & Resolution